The Bulgarian pharmaceutical industry is calling for a 14% funding increase in 2027, warning that the current reimbursement model is becoming increasingly difficult to sustain
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.